Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Intuitive Surgical Inc Market Cap
The Intuitive Surgical Inc (ISRG) share price is expected to increase by 10.39% over the next year. This is based on calculating the average 12-month share price estimate provided by 18 stock analysts who have covered ISRG. Price targets range from $370.00 at the low end to $475.00 at the high end. The current analyst consensus for ISRG is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Intuitive Surgical Inc has a total of 18 Wall St Analyst ratings. There are 13 buy ratings, 5 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Intuitive Surgical Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| david toung Argus Research | Buy | $450.0 | maintained | Feb 8, 2024 |
| adam maeder Piper Sandler | Buy | $425.0 | reiterated | Feb 6, 2024 |
| ryan zimmerman BTIG | Buy | $412.0 | rated | Jan 29, 2024 |
| drew ranieri Morgan Stanley | Hold | $375.0 | maintained | Jan 25, 2024 |
| suraj kalia Oppenheimer | Hold | None | maintained | Jan 24, 2024 |
| joanne wuensch Citi | Buy | $428.0 | maintained | Jan 24, 2024 |
| matt miksic Barclays | Buy | $430.0 | reiterated | Jan 24, 2024 |
| robbie marcus J.P. Morgan | Buy | $475.0 | maintained | Jan 24, 2024 |
| rick wise Stifel Nicolaus | Buy | $420.0 | rated | Jan 24, 2024 |
| richard newitter Truist Financial | Buy | $435.0 | maintained | Jan 24, 2024 |
| vijay kumar Evercore ISI | Hold | $385.0 | maintained | Jan 24, 2024 |
| imron zafar Deutsche Bank | Hold | $370.0 | maintained | Jan 24, 2024 |
| anthony petrone Mizuho Securities | Hold | $390.0 | rated | Jan 24, 2024 |
| mike kratky Leerink Partners | Buy | $436.0 | reiterated | Jan 24, 2024 |
| david rescott Robert W. Baird | Buy | $440.0 | rated | Jan 24, 2024 |
| shagun singh chadha RBC Capital | Buy | $432.0 | reiterated | Jan 23, 2024 |
| larry biegelsen Wells Fargo | Buy | $416.0 | maintained | Jan 23, 2024 |
| danielle antalffy UBS | Hold | $385.0 | maintained | Jan 22, 2024 |
| travis steed Bank of America Securities | Buy | $400.0 | maintained | Jan 10, 2024 |
| helen fang HSBC | Buy | $318.0 | initiatedcoverage | Nov 17, 2023 |
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
When did it IPO
2000
Staff Count
13,676
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Dr. Gary S. Guthart Ph.D.
Market Cap
$133.40B
In 2023, ISRG generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ISRG's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$198.94
LRCX-USD
$926.03
PANW-USD
$366.41
AMGN-USD
$285.18
AMAT-USD
$199.73
$254.76
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
